Dergiler / Turkish Journal of Chemistry / 2020 / Cilt: 44 - Sayı: 6

Synthesis and pharmacological effects of novel benzenesulfonamides carrying benzamide moiety as carbonic anhydrase and acetylcholinesterase inhibitors

Sayfa
1601–1609
Yayın Tarihi
2022-11-01
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Secondary sulfonamides showed promising enzyme inhibitory effects on AChE while primary sulfonamide derivative was generally effective on hCA I and hCA II isoenzymes.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:N-(1-(4-Methoxyphenyl)-3-oxo-3-((4-(N-(substituted)sulfamoyl)phenyl)amino)prop-1-en-1-yl)benzamides 3a – g were designed since sulfonamide and benzamide pharmacophores draw great attention in novel drug design due to their wide range of bioactivities including acetylcholinesterase (AChE) and human carbonic anhydrase I and II (hCA I and hCA II) inhibitory potencies.
📊
Temel Bulgular & Veri:Structure elucidation of the compounds was carried out by 1 H NMR, $^{13}C NMR$, and HRMS spectra.
💡
Sonuç & Katkı:Secondary sulfonamides showed promising enzyme inhibitory effects on AChE while primary sulfonamide derivative was generally effective on hCA I and hCA II isoenzymes.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

N-(1-(4-Methoxyphenyl)-3-oxo-3-((4-(N-(substituted)sulfamoyl)phenyl)amino)prop-1-en-1-yl)benzamides 3a – g were designed since sulfonamide and benzamide pharmacophores draw great attention in novel drug design due to their wide range of bioactivities including acetylcholinesterase (AChE) and human carbonic anhydrase I and II (hCA I and hCA II) inhibitory potencies. Structure elucidation of the compounds was carried out by 1 H NMR, $^{13}C NMR$, and HRMS spectra. In vitro enzyme assays showed that the compounds had significant inhibitory potential against hCA I, hCA II, and AChE enzymes at nanomolar levels. Ki values were in the range of 4.07 ± 0.38 – 29.70 ± 3.18 nM for hCA I and 10.68 ± 0.98 – 37.16 ± 7.55 nM for hCA II while Ki values for AChE were in the range of 8.91 ± 1.65 – 34.02 ± 5.90 nM. The most potent inhibitors 3g (Ki = 4.07 ± 0.38 nM, hCA I), 3c (Ki = 10.68 ± 0.98 nM, hCA II), and 3f (Ki = 8.91 ± 1.65 nM, AChE) can be considered as lead compounds of this study with their promising bioactivity results. Secondary sulfonamides showed promising enzyme inhibitory effects on AChE while primary sulfonamide derivative was generally effective on hCA I and hCA II isoenzymes.

🔖

Bu Makaleye Atıf Yap

GÜLÇİN, İ., ANIL, B., GÜL, H. İ., TUĞRAK, M. (2022). Synthesis and pharmacological effects of novel benzenesulfonamides carrying benzamide moiety as carbonic anhydrase and acetylcholinesterase inhibitors. Turkish Journal of Chemistry, Cilt: 44 - Sayı: 6, 1601–1609. https://ajindex.com/articles/601605

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (1)

  1. Akı-Şener E, Bingöl KK, Temiz-Arpacı Ö, Yalçın İ, Altanlar N. Synthesis and microbiological activity of some N-(2-hydroxy-4-substituted phenylbenzamides, phenylacetamides and furamides as the possible metabolites of antimicrobial active benzoxazoles. Il Farmaco 2002; 57 (6): 451-456. doi: 10.1016/s0014-827x(02)01226-0 2. Akı Şener E, Bingöl KK, Ören İ, Temiz Arpacı Ö, Yalçın İ et al. Synthesis and microbiological activity of some N-(o-hydroxyphenyl) benzamides and phenylacetamides as the possible metabolites of antimicrobial active benzoxazoles: part II. Il Farmaco 2000; 55 (6-7): 469-476. doi: 10.1016/s0014-827x(00)00070-7 3. Pau A, Boatto G, Palomba M, Asproni B, Cerri R et al. Synthesis of N-[4-(alkyl)cyclohexyl]-substituted benzamides with antiinflammatory and analgesic activities. Il Farmaco 1999; 54 (8): 524-532. doi: 10.1016/s0014-827x(99)00057-9 4. Asif M. Pharmacological potential of benzamide analogues and their uses in medicinal chemistry. Modern Chemistry Applications 2016; 4 (4): 1-10. doi: 10.4172/2329-6798.1000194 5. Bondi MW, Edmonds EC, Salmon DP. Alzheimer’s disease: past, present, and future. Journal of the International Neuropsychological Society 2017; 23 (9-10): 818-831. doi: 10.1017/S135561771700100X 6. Karlawish J, Jack CR, Rocca WA, Snyder HM, Carrillo MC. Alzheimer’s disease: the next frontier-special report 2017. Alzheimers Dement 2017; 13 (4): 374-380. doi: 10.1016/j.jalz.2017.02.006 7. Realdon O, Rossetto F, Nalin M, Baroni I, Cabinio M et al. Technology-enhanced multi-domain at home continuum of care program with respect to usual care for people with cognitive impairment: the Ability-TelerehABILITation study protocol for a randomized controlled trial. BMC Psychiatry 2016; 16: 425-433. doi: 10.1186/s12888-016-1132-y 8. Sobolova K, Hrabinova M, Hepranova V, Kucera T, Tereza Kobrlova T et al. Discovery of novel berberine derivatives with balanced cholinesterase and prolyl oligopeptidase inhibition profile. European Journal of Medicinal Chemistry 2020; 203: 112593. doi: 10.1016/j. ejmech.2020.112593 9. Sawatzky E, Wehle S, Kling B, Wendrich J, Bringmann G et al. Discovery of highly selective and nanomolar carbamate-based butyrylcholinesterase inhibitors by rational investigation into their inhibition mode. Journal of Medicinal Chemistry 2016; 59 (5): 2067- 2082. doi: 10.1021/acs.jmedchem.5b01674 10. Darvesh S. Butyrylcholinesterase as a diagnostic and therapeutic target for Alzheimer’s disease. Current Alzheimer Research 2016; 1